Live Breaking News & Updates on David Soergel

Stay updated with breaking news from David soergel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF – IT Business Net

Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

New York , United States , Eric Althoff , Isabella Zinck , David Soergel , Thomas Hungerbuehler , Coll Cardiol , Samir Shah , Scott Solomon , Sloan Simpson , Phil Mcnamara , American Heart Association , Committee Co , Novartis External Communications , Metabolic Drug Development , Metabolism Communications , Us Department Of Health , Human Services , Renal Drugs Advisory Committee , Drug Administration , Professor Of Medicine At Harvard Medical School , Novartis Us External Communications , Exchange Commission , Novartis Pharmaceuticals Corp , Hf New York Heart Association , New Drug Application ,

Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat pati

Search jobs
16-Dec-2020
Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF
EAST HANOVER, December 15, 2020 /PRNewswire/ Novartis today announced that the US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 12 to 1 that the data presented support the use of Entresto
® (sacubitril/valsartan) in treatment of patients with heart failure with preserved ejection fraction (HFpEF). This was based on data supporting the benefit of Entresto in reducing worsening heart failure (total heart failure [HF] hospitalizations and urgent HF visits) in patients studied in PARAGON-HF. If approved by the FDA, Entresto could become the first therapy indicated for use in treatment of patients with HFpEF, as well as the first medication approved for both major types of chronic heart failure, HFpEF and heart failure with reduc ....

United States , Coll Cardiol , Eric Althoff , Jamie Bennett , David Soergel , Sloan Simpson , Scott Solomon , Us Corp Country External Comms , American Heart Association , Committee Co , Metabolic Drug Development , Global Media Corp Communications , Us Department Of Health , Human Services , Renal Drugs Advisory Committee , Drug Administration , Professor Of Medicine At Harvard Medical School , Exchange Commission , Novartis Pharmaceuticals Corporation , Nj Novartis Pharmaceuticals Corporation , Novartis Pharmaceuticals Corp , New Drug Application , Harvard Medical School , Global Head , New England Journal , Prescribing Information ,